“
“MedImmune,

Gaithersburg, MD, USA In this study, we have analyzed the in vivo dynamics of the interaction between polyclonal Foxp3+ Treg cells, effector T (Teff) cells, and DCs in order to further our understanding of the mechanisms of Treg cell-mediated Navitoclax manufacturer suppression. Cotransfer of polyclonal activated Treg cells into healthy mice attenuated the induction of EAE. Suppression of disease strongly correlated with a reduced number of Teff cells in the spinal cord, but not with Treg cell-mediated inhibition of Th1/Th17 differentiation. Cotransfer of Treg cells with TCR-Tg Teff cells followed by immunization by multiple routes resulted in an enhanced number of Teff cells in the lymph nodes draining the site of immunization without an inhibition of Teff-cell differentiation. Fewer Teff cells could be detected in the blood in the presence of Treg cells and fewer T cells could access a site of antigen exposure in a modified delayed-type hypersensitivity assay. Teff cells recovered from LNs in the presence of Treg cells expressed decreased levels of CXCR4, syndecan, and the sphingosine phosphate receptor, S1P1 (sphingosine 1-phosphate receptor 1). Thus, polyclonal Treg cells influence Teff-cell

responses by targeting trafficking pathways, thus allowing immunity to develop in lymphoid organs, but limiting the number of potentially auto-aggressive cells that are allowed to enter the tissues. Numerous mechanisms exist to both activate and dampen immune responses. A primary cell type involved in immune suppression is the selleck inhibitor thymic-derived Treg cell defined by the expression of the transcription factor Foxp3. Mutations in Foxp3 lead to severe defects of immunological homeostasis in both mouse and human 1. Treg cells have also been shown to play a pivotal role in numerous disease settings, including autoimmunity, infection, and tumor progression 2. Multiple mechanisms have been proposed for suppressor function of Treg cells including the secretion of suppressive cytokines, direct cytolysis of T effector (Teff) cells, metabolic disruption through tryptophan catabolites,

adenosine or IL-2 deprivation, and direct interference of co-stimulation via expression of CTLA-4 3. Given the obvious interest in targeting Treg cells in various disease settings through pharmacological intervention, DAPT purchase a more definitive understanding of their mechanism of action is warranted. To achieve this, the in vivo dynamics of the interaction between Treg cells, Teff cells, and DCs need to be more thoroughly evaluated. Upon immunological challenge, DCs capture antigen and migrate to draining LNs where they present the antigen to Teff cells 4. The Teff cells then become activated and undergo several rounds of division during which time they differentiate. After this has occurred, Teff cells leave the LN, enter the circulation, and ultimately enter tissues. All of these steps represent potential checkpoints where Treg cells may exert their influence.